Observational studyScientific reports2017
CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma.
Observational study in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Diagnostic Performance of Computed Tomography-Based Artificial Intelligence for Early Recurrence of Cholangiocarcinoma: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2025Pooled it
- Collagen turnover biomarkers to predict outcome of patients with biliary cancer.BMC gastroenterology · 2025Trial
- A preoperative scoring system to predict lymph node metastasis in intrahepatic cholangiocarcinoma.Hepatology international · 2023Trial
- Anatomic-Biologic Borderline Resectability Criteria Improve Recurrence Risk Stratification in Perihilar Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Association Between Multi-Laboratory Parameters Pre- and Post-Treatment and Pathological Features and Their Values in Clinical Decision in Primary Hepatic Carcinoma.Journal of clinical laboratory analysis · 2026Article
- Value of Imaging Parameters of [Molecular imaging and biology · 2026Article
- Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab.Targeted oncology · 2026Article
- Patterns and risk factors of early recurrence after radical resection for intrahepatic cholangiocarcinoma.World journal of gastrointestinal surgery · 2026Article
- Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions.Frontiers in oncology · 2026Review
- Integrating Etiological Insights With Machine Learning for Precision Diagnosis of Obstructive Jaundice: Findings From a High-Volume Center.Clinical and translational gastroenterology · 2025Observational
- Preoperative total bile acid can be used as a prognostic biomarker in patients with operable biliary tract cancers.Discover oncology · 2025Article
- Performance of large language models in the differential diagnosis of benign and malignant biliary stricture.Frontiers in oncology · 2025Article
- UPLC-Q-TOF-MS-based unbiased serum metabolomics investigation of cholangiocarcinoma.Frontiers in molecular biosciences · 2025Article
- The prognostic impact of preoperative CA19-9 on resectable cholangiocarcinoma: a comprehensive systematic review and meta-analysis.Discover oncology · 2024Article
- Diagnostic value of carbohydrate antigen 50 in biliary tract cancer: A large-scale multicenter study.Cancer medicine · 2024Article
- Practice guidelines for managing extrahepatic biliary tract cancers.Annals of hepato-biliary-pancreatic surgery · 2024Article
- Carcinoembryonic antigen in the diagnosis, treatment, and follow-up of focal liver lesions.World journal of gastrointestinal surgery · 2024Article
- Impact of radiological and pathological splenic vein involvement in patients with resectable pancreatic body or tail cancer.Langenbeck's archives of surgery · 2024Article
- Article
- Fish and Food-Fatale: Food-borne TrematodeHelminthologia · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) represents a rare form of primary liver cancer with increasing incidence but dismal prognosis. Surgical treatment has remained the only potentially curative treatment option, but it remains unclear which patients benefit most from liver surgery, highlighting the need for new preoperative stratification strategies. In clinical routine, CA19-9 represents the most widely used tumor marker in CCA patients. However, data on the prognostic value of CA19-9 in CCA patients are limited and often inconclusive, mostly due to small cohort sizes. Here, we investigated the prognostic value of CA19-9 in comparison with other standard laboratory markers in a large cohort of CCA patients that underwent tumor resection. Of note, while CA19-9 and CEA were able to discriminate between CCA and healthy controls, CEA showed a higher accuracy for the differentiation between CCA and patients with primary sclerosing cholangitis (PSC) compared to CA19-9. Furthermore, patients with elevated levels of C-reactive protein (CRP), CA19-9 or CEA showed a significantly impaired survival in Kaplan-Meier curve analysis, but surprisingly, only CEA but not CA19-9 represented an independent predictor of survival in multivariate Cox-regression analysis. Our data suggest that CEA might help to identify CCA patients with an unfavourable prognosis after tumor resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.